Association of health-related quality of life (HRQOL) variations with biological biomarkers for patients with metastatic castrate-resistant prostate cancer (MCRPC) treated by abiraterone/prednisone combination or prednisone.

被引：0
|
作者：
Goujon, Morgan [1 ]
Anota, Amelie [2 ,3 ]
Charton, Frontczak Alexandre [4 ]
Charton, Emilie [5 ,6 ]
Maurina, Tristan [1 ]
Almotlak, Hamadi [1 ]
Nguyen, Thierry [1 ]
Fabien, Calcagno [1 ]
Stein, Ulrich [1 ]
Mouillet, Guillaume [7 ]
Thiery-Vuillemin, Antoine [8 ]
机构：
[1] Univ Hosp, Dept Med Oncol, Besancon, France
[2] Univ Hosp Besancon, Qual Life Oncol Clin Res Platform, Besancon, France
[3] Univ Hosp Besancon, Methodol & Qual Life Oncol, INSERM UMR 1098, Besancon, France
[4] Univ Hosp, Dept Urol, Besancon, France
[5] Univ Hosp Besancon, Methodol & Qual Life Unit, Dept Oncol, INSERM UMR 1098, Besancon, France
[6] French Natl Platform Qual Life & Canc, Besancon, France
[7] Univ Hosp, Dept Med Oncol, Methodol & Qual Life Unit Oncol, INSERM UMR 1098, Besancon, France
[8] Univ Hosp, Dept Med Oncol, INSERM UMR 1098, Besancon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.54
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
54
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Real-world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer: The Singapore experience
    Chan, Johan
    Yap, Shi Yin
    Fong, Yian Ching
    Lim, Heng Chi
    Toh, Chee Keong
    Ng, Quan Sing
    Rajasekaran, Tanujaa
    Chua, Melvin
    Lee, Lui Shiong
    Wong, Alvin
    Loh, Ker Yun
    Chow, Marcus
    Wong, Siew Wei
    Kanesvaran, Ravindran
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (01) : 75 - 79
  • [32] Phase I trial of docetaxel (D), prednisone, and pasireotide (P) (SOM230) in metastatic castrate-resistant prostate cancer (mCRPC).
    Vankayala, Hema M.
    Heilbrun, Lance K.
    Dobson, Kimberlee
    Stark, Karri
    Li, Jing
    Smith, Daryn W.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Strauss, Julius
    Chun, Guinevere
    Couvillon, Anna
    Harold, Nancy
    Chen, Clara
    Dawson, Nancy Ann
    Apolo, Andrea Borghese
    Steinberg, Seth M.
    Trepel, Jane B.
    Wright, John Joseph
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC).
    Kohli, Manish
    Qin, Rui
    Wang, Liguo
    Sicotte, Hugues
    Carlson, Rachel
    Tan, Winston
    Jimenez, Rafael E.
    Wang, Liewei
    Eckel-Passow, Jeanette
    Costello, Brian Addis
    Pitot, Henry C.
    Quevedo, Fernando
    Dronca, Roxana Stefania
    Wu, Kevin
    Moynihan, Timothy Jerome
    Thai Huu Ho
    Bryce, Alan Haruo
    Atwell, Thomas D.
    McMenomy, Brendan P.
    Dehm, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial
    Khalaf, Daniel J.
    Sunderland, Katherine
    Eigl, Bernhard J.
    Kollmannsberger, Christian K.
    Ivanov, Nikita
    Finch, Daygen L.
    Oja, Conrad
    Vergidis, Joanna
    Zulfiqar, Muhammad
    Gleave, Martin E.
    Chi, Kim N.
    EUROPEAN UROLOGY, 2019, 75 (06) : 940 - 947
  • [36] Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Abida, W.
    Iannotti, N.
    Argon, E. Kocabas
    Appleman, L.
    Michaud, N.
    Rajarethinam, A.
    Adib, D.
    Saltzstein, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S636 - S636
  • [37] Testing a prognostic model in patients with metastatic castrate resistant prostate cancer (MCRPC) treated prechemotherapy with abiraterone.
    Pan, Shermaine
    Prasad, Kellati
    Hall, Emma
    Swindell, Ric
    Charnley, Natalie
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [38] Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low- vs. high-risk of radiographic progression: An analysis of COU-AA-302
    Martin, Lisa J.
    Alibhai, Shabbir M. H.
    Komisarenko, Maria
    Timilshina, Narhari
    Finelli, Antonio
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (06): : 192 - 200
  • [39] Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients
    Lloyd, Andrew J.
    Kerr, Cicely
    Penton, James
    Knerer, Gerhart
    VALUE IN HEALTH, 2015, 18 (08) : 1152 - 1157
  • [40] Switch from abiraterone plus prednisone to abiraterone plus dexamethasone after PSA progression under abiraterone plus prednisone in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients
    Fenioux, C.
    Louvet, C.
    Prapotnich, D.
    Ropert, S.
    Barret, E.
    Sanchez-Salas, R.
    Mombet, A.
    Cathala, N.
    Poullennec, B.
    Joulia, M-L.
    Ung, M.
    Cathelineau, X.
    Bennamoun, M.
    ANNALS OF ONCOLOGY, 2016, 27
12345